Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals board meeting scheduled for May 29, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026. Board will consider recommending dividend for FY2026 on equi

Glenmark Pharmaceuticals Inc., USA launched Vancomycin Hydrochloride for Injection USP in 500 mg/vial and 1 g/vial strengths. The product is bioequivalent to Fresenius Kabi's reference drug and addres